Clinical Stakeholders' Perceptions of Patient Engagement in Outpatient Medication Treatment for Opioid Use Disorder: A Qualitative Study

Overview

Journal J Subst Use Addict Treat

Specialty Psychiatry

Date 2023 Dec 10

PMID 38072381

Authors

Melissa N Poulsen

Sophie A Roe

Patrick B Asdell

Alanna Kulchak Rahm

Wade Berrettini

Affiliations

Soon will be listed here.

Abstract

Introduction: Medications for opioid use disorder (MOUD) reduce risk of opioid overdose and promote recovery from opioid use disorder, but poor retention in MOUD limits these positive effects. This study explored patient engagement in MOUD from the perspective of clinical stakeholders within an outpatient addiction medicine program to identify program factors influencing patient engagement with treatment.

Methods: We conducted a qualitative case study of a multi-clinic outpatient addiction medicine program embedded within an integrated health system that serves a geographically diverse area of Pennsylvania. Collectively, the program's clinics provide MOUD (primarily buprenorphine) to ~2000 patients annually. From January to March 2021, we conducted semi-structured telephone/video interviews with three stakeholder groups involved in delivering MOUD: administrators (n = 4), providers (n = 7), and addiction care coordinators (n = 5). Data analysis utilized the framework method.

Results: We identified five themes related to patient engagement. First, participants described health system integration as enhancing quality and offering opportunities for addressing patients' comprehensive health care needs. However, lack of knowledge about addiction and stigma among health system providers was felt to limit patient benefits from this integration, including access to MOUD. Second, participants viewed patient engagement as central to the program's policies, practices, and clinical environment. Adoption of a harm reduction approach and maintenance of a non-stigmatizing clinic environment were described as essential facilitators of engagement. Third, while clinics followed uniform operations, physician leads expressed differing philosophical approaches to treatment, which participants associated with variations in clinical practice and patient engagement. Fourth, participants identified key services that bolstered engagement in MOUD, including psychosocial services, psychiatric care, and telemedicine. Finally, staff well-being emerged as a key consideration for patient engagement.

Conclusions: Understanding perceptions of those who administer and deliver care is critical for identifying barriers and facilitators to patient engagement in MOUD. Findings suggest potential opportunities for addiction treatment programs to improve patient engagement and ultimately MOUD retention, including integration with other healthcare services to meet comprehensive healthcare needs; adoption of a harm reduction approach; creation of non-stigmatizing clinical environments; investment in psychosocial services, psychiatric care, and telemedicine; and prioritization of staff wellness.

References

Filteau M, Kim F, Green B . "It's more than Just a Job to Them": A Qualitative Examination of Patient and Provider Perspectives on Medication-Assisted Treatment for Opioid Use Disorder. Community Ment Health J. 2021; 58(2):321-327. DOI: 10.1007/s10597-021-00824-7. View

Santo Jr T, Clark B, Hickman M, Grebely J, Campbell G, Sordo L . Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021; 78(9):979-993. PMC: 8173472. DOI: 10.1001/jamapsychiatry.2021.0976. View

Najavits L, Crits-Christoph P, Dierberger A . Clinicians' impact on the quality of substance use disorder treatment. Subst Use Misuse. 2001; 35(12-14):2161-90. DOI: 10.3109/10826080009148253. View

Brown A . Health professionals' attitudes toward medications for opioid use disorder. Subst Abus. 2021; 43(1):598-614. DOI: 10.1080/08897077.2021.1975872. View

Poulsen M, Santoro W, Scotti R, Henderson C, Ruddy M, Colistra A . Implementation of Telemedicine Delivery of Medications for Opioid Use Disorder in Pennsylvania Treatment Programs During COVID-19. J Addict Med. 2022; 17(2):e110-e118. PMC: 10022523. DOI: 10.1097/ADM.0000000000001079. View

Tong A, Sainsbury P, Craig J . Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007; 19(6):349-57. DOI: 10.1093/intqhc/mzm042. View

Spencer M, Minino A, Warner M . Drug Overdose Deaths in the United States, 2001-2021. NCHS Data Brief. 2023; (457):1-8. View

Cioe K, Biondi B, Easly R, Simard A, Zheng X, Springer S . A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder. J Subst Abuse Treat. 2020; 119:108146. PMC: 7609980. DOI: 10.1016/j.jsat.2020.108146. View

Lister J, Weaver A, Ellis J, Himle J, Ledgerwood D . A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Am J Drug Alcohol Abuse. 2019; 46(3):273-288. DOI: 10.1080/00952990.2019.1694536. View

10.

Scorsone K, Haozous E, Hayes L, Cox K . Overcoming Barriers: Individual Experiences Obtaining Medication-Assisted Treatment for Opioid Use Disorder. Qual Health Res. 2020; 30(13):2103-2117. DOI: 10.1177/1049732320938689. View

11.

Glanz J, Binswanger I, Clarke C, Nguyen A, Ford M, Ray G . The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment. Addiction. 2022; 118(1):97-107. PMC: 9722535. DOI: 10.1111/add.15998. View

12.

Gale N, Heath G, Cameron E, Rashid S, Redwood S . Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013; 13:117. PMC: 3848812. DOI: 10.1186/1471-2288-13-117. View

13.

Kahn L, Wozniak M, Doscher T, Moore C, Vest B . Treatment Experiences Among People Who Use Opioids: A Social Ecological Approach. Qual Health Res. 2022; 32(8-9):1386-1398. DOI: 10.1177/10497323221104315. View

14.

Bentzley B, Barth K, Back S, Book S . Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abuse Treat. 2015; 52:48-57. PMC: 4382404. DOI: 10.1016/j.jsat.2014.12.011. View

15.

Lai S, Li E, Silverio A, DeBates R, Kelly E, Weinstein L . "It's a place that gives me hope": A qualitative evaluation of a buprenorphine-naloxone group visit program in an urban federally qualified health center. Subst Abus. 2021; 42(4):858-864. DOI: 10.1080/08897077.2021.1876202. View

16.

OConnor A, Cousins G, Durand L, Barry J, Boland F . Retention of patients in opioid substitution treatment: A systematic review. PLoS One. 2020; 15(5):e0232086. PMC: 7224511. DOI: 10.1371/journal.pone.0232086. View

17.

Mackey K, Veazie S, Anderson J, Bourne D, Peterson K . Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review. J Gen Intern Med. 2020; 35(Suppl 3):954-963. PMC: 7728943. DOI: 10.1007/s11606-020-06257-4. View

18.

Poulsen M, Asdell P, Berrettini W, McBryan K, Rahm A . Application of the COM-B model to patient barriers and facilitators of retention in medication treatment for opioid use disorder in rural Northeastern United States: A qualitative study. SSM Ment Health. 2023; 2. PMC: 9912293. DOI: 10.1016/j.ssmmh.2022.100151. View

19.

Beharie N, Kaplan-Dobbs M, Urmanche A, Paone D, Harocopos A . "I didn't feel like a number": The impact of nurse care managers on the provision of buprenorphine treatment in primary care settings. J Subst Abuse Treat. 2021; 132:108633. PMC: 10089662. DOI: 10.1016/j.jsat.2021.108633. View

20.

Kankanam Gamage K, Tejpar S, Majid U, Dixon K, Sabioni P, Sud A . Bridging the Macro-micro Divide: A Qualitative Meta-synthesis on the Perspectives and Experiences of Health Care Providers on the Extramedical Use and Diversion of Buprenorphine. J Addict Med. 2022; 17(1):e1-e10. PMC: 9897281. DOI: 10.1097/ADM.0000000000001020. View